Faculty

Back to Index
Afsaneh Barzi, MD
Assistant Professor of Clinical Medicine
Medical Director
Medicine
NOR 3440 Health Sciences Campus Los Angeles
+1 323 865 3829

Overview

Barzi earned her M.D. from Tehran University of Medical Sciences, then went on to earn a Master’s in Health Informatics and a Doctorate in Public Health Management and Policy Sciences from the University of Texas Health Science Center in Houston. She recently completed a fellowship in hematology and oncology at the Cleveland Clinic’s Taussig Cancer Center.

Her research interests are the development of new cancer therapies as well as healthcare economics and metrics of healthcare quality for improving patient care. Dr. Barzi has proposed a phase II study to investigate the overall survival benefit of adding lapatinib to docetaxel in a second line setting in patients with trastuzumab-resistant, HER2-positive gastric cancer.

“Delivery of personalized treatment to gastric cancer patients has lagged behind other diseases,” Barzi says. “My goal is to establish a second-line treatment for these patients that are HER2-positive and to better understand the mechanisms of resistance to HER2-targeted therapy, paving the way for new therapies that can overcome that resistance.”

Awards

National Cancer Institute: Travel Award for Markers in Cancer, 2013

Southwest Oncology Group: Young Investigator Award, 2011

Southwest Oncology Group: award conferred by, 2011

National Cancer Institute: award conferred by, 2013

Southwest Oncology Group: ORNG Application Instance for Person, 2011

National Cancer Institute: ORNG Application Instance for Person, 2013

Southwest Oncology Group: start date, 2011

National Cancer Institute: start date, 2013

National Cancer Institute: full name, 2013

Southwest Oncology Group: full name, 2011

National Cancer Institute: ORNG Application Instance Data value, 2013

Southwest Oncology Group: ORNG Application Instance Data value, 2011

Southwest Oncology Group: person in primary position, 2011

National Cancer Institute: person in primary position, 2013

Southwest Oncology Group: is primary position, 2011

National Cancer Institute: is primary position, 2013

National Cancer Institute: last name, 2013

Southwest Oncology Group: last name, 2011

Southwest Oncology Group: ORNG Application URL, 2011

National Cancer Institute: ORNG Application URL, 2013

Southwest Oncology Group: Barzi, Afsaneh, 2011

National Cancer Institute: Barzi, Afsaneh, 2013

Southwest Oncology Group: Department, 2011

National Cancer Institute: Department, 2013

Southwest Oncology Group: sort order, 2011

National Cancer Institute: sort order, 2013

Southwest Oncology Group: Person, 2011

Southwest Oncology Group: Assistant Professor, 2011

National Cancer Institute: Assistant Professor, 2013

Southwest Oncology Group: ClinicalTrials, 2011

National Cancer Institute: ClinicalTrials, 2013

National Cancer Institute: email address, 2013

Southwest Oncology Group: email address, 2011

Southwest Oncology Group: Required Scholarly Project Mentor, 2011

National Cancer Institute: Required Scholarly Project Mentor, 2013

Southwest Oncology Group: Person ID, 2011

National Cancer Institute: Person ID, 2013

Southwest Oncology Group: ct_data, 2011

National Cancer Institute: ct_data, 2013

National Cancer Institute: label, 2013

Southwest Oncology Group: label, 2011

National Cancer Institute: position in organization, 2013

Southwest Oncology Group: position in organization, 2011

National Cancer Institute: Organization, 2013

Southwest Oncology Group: Organization, 2011

National Cancer Institute: Assistant Professor of Clinical Medicine, 2013

Southwest Oncology Group: Assistant Professor of Clinical Medicine, 2011

National Cancer Institute: Person, 2013

National Cancer Institute: preferred title, 2013

Southwest Oncology Group: preferred title, 2011

Southwest Oncology Group: first name, 2011

National Cancer Institute: first name, 2013

National Cancer Institute: Agent, 2013

Southwest Oncology Group: Agent, 2011

National Cancer Institute: Medicine, 2013

Southwest Oncology Group: Medicine, 2011

National Cancer Institute: has ORNG Application Instance Data, 2013

Southwest Oncology Group: has ORNG Application Instance Data, 2011

National Cancer Institute: RequiredScholarlyProjectMentor, 2013

Southwest Oncology Group: RequiredScholarlyProjectMentor, 2011

Southwest Oncology Group: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^169-123, 2011

National Cancer Institute: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^169-123, 2013

National Cancer Institute: Award or Honor Receipt, 2013

Southwest Oncology Group: Award or Honor Receipt, 2011

Southwest Oncology Group: Faculty Rank, 2011

National Cancer Institute: Faculty Rank, 2013

National Cancer Institute: Keck School of Medicine of USC, 2013

Southwest Oncology Group: Position, 2011

National Cancer Institute: Position, 2013

National Cancer Institute: HR job title, 2013

Southwest Oncology Group: HR job title, 2011

Southwest Oncology Group: has faculty rank, 2011

National Cancer Institute: has faculty rank, 2013

National Cancer Institute: position in department, 2013

Southwest Oncology Group: position in department, 2011

National Cancer Institute: ORNG Application Instance of Application, 2013

Southwest Oncology Group: ORNG Application Instance of Application, 2011

Publications

Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clin Colorectal Cancer. 2016 Dec; 15(4):e221-e227. View in: PubMed

Stomach cancer disparity among Korean Americans by tumor characteristics: comparison with non-Hispanic whites, Japanese Americans, South Koreans, and Japanese. Cancer Epidemiol Biomarkers Prev. 2016 Dec 01. View in: PubMed

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Jul 19. View in: PubMed

Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. View in: PubMed

Lost in Translation: The Patient-Physician Relationship in the Molecular Era. J Palliat Med. 2015 Nov; 18(11):987-8. View in: PubMed

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. View in: PubMed

We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. J Adolesc Young Adult Oncol. 2015 Sep 1; 4(3):105-7. View in: PubMed

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Ann Oncol. 2015 Aug; 26(8):1728-33. View in: PubMed

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. View in: PubMed

Comparative effectiveness of screening strategies for lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). View in: PubMed

Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3). View in: PubMed

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015 Feb; 26(2):332-9. View in: PubMed

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. View in: PubMed

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. View in: PubMed

Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opin Biol Ther. 2014 Sep; 14(9):1319-32. View in: PubMed

Timeliness of Adjuvant Chemotherapy for Stage III Adenocarcinoma of the Colon: A Measure of Quality of Care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. View in: PubMed

Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res. 2013 Nov 1; 19(21):5842-8. View in: PubMed

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013 Oct; 12(10):2261-72. View in: PubMed

Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. View in: PubMed

Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. View in: PubMed

Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med. 2010 Jan; 77(1):37-44. View in: PubMed

A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. View in: PubMed

Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. View in: PubMed

Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. View in: PubMed

Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer. Tumori. 1979 Jun 30; 65(3):339-44. View in: PubMed

Powered bySC CTSI